China AI drug-design deals swell as US scrutiny mounts - South China Morning Post

Chinese companies are increasing deals to use AI for drug discovery while facing increased scrutiny from the U.S. government. This reflects geopolitical competition in advanced AI applications with implications for healthcare innovation.